Oncoretroviral and lentiviral vector-mediated gene therapy

Thierry VandenDriessche, Luigi Naldini, Desire Collen, Marinee K L Chuah

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Oncoretroviral vectors and lentiviral vectors offer the potential for long-term gene expression by virtue of their stable chromosomal integration and lack of viral gene expression. Consequently, their integration allows passage of the transgene to all progeny cells, which makes them particularly suitable for stem cell transduction. However, a disadvantage of oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV) is that cell division is required for transduction and integration, thereby limiting oncoretroviral-mediated gene therapy to actively dividing target cells. In contrast, lentiviral vectors can transduce both dividing and nondividing cells. Lentiviral vectors have been derived from either human or primate lentiviruses, with the human immunodeficiency virus (HIV) as prototype, or from nonprimate lentiviruses, such as the equine infectious anemia virus (EIAV). The ability to pseudotype oncoretroviral and lentiviral vectors with the vesicular stomatitis virus G glycoprotein (VSV-G) allowed for the production of high-titer vectors (10 9-10 transducing units/ml). These high-titer vector preparations were shown to effectively cure genetic diseases in experimental animal models and constitute an essential step toward direct in vivo gene therapy applications. This chapter focuses on different methods that permit large-scale production of high-titer VSV-G pseudotyped oncoretroviral and primate or nonprimate lentiviral vectors and highlights their importance for achieving therapeutic effects in preclinical animal models.

Original languageEnglish
Article number33
Pages (from-to)573-589
Number of pages17
JournalMethods in Enzymology
Volume346
DOIs
Publication statusPublished - 2002

Fingerprint

Gene therapy
Genetic Therapy
Vesicular Stomatitis
Glycoproteins
Viruses
Primate Lentiviruses
Animal Models
Equine infectious anemia virus
Moloney murine leukemia virus
Gene Expression
Lentivirus
Inborn Genetic Diseases
Viral Genes
Therapeutic Uses
Transgenes
Cell Division
Primates
Stem Cells
HIV
Gene expression

ASJC Scopus subject areas

  • Biochemistry

Cite this

Oncoretroviral and lentiviral vector-mediated gene therapy. / VandenDriessche, Thierry; Naldini, Luigi; Collen, Desire; Chuah, Marinee K L.

In: Methods in Enzymology, Vol. 346, 33, 2002, p. 573-589.

Research output: Contribution to journalArticle

VandenDriessche, Thierry ; Naldini, Luigi ; Collen, Desire ; Chuah, Marinee K L. / Oncoretroviral and lentiviral vector-mediated gene therapy. In: Methods in Enzymology. 2002 ; Vol. 346. pp. 573-589.
@article{52b737a9530343b295a71c6fb23c2d6e,
title = "Oncoretroviral and lentiviral vector-mediated gene therapy",
abstract = "Oncoretroviral vectors and lentiviral vectors offer the potential for long-term gene expression by virtue of their stable chromosomal integration and lack of viral gene expression. Consequently, their integration allows passage of the transgene to all progeny cells, which makes them particularly suitable for stem cell transduction. However, a disadvantage of oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV) is that cell division is required for transduction and integration, thereby limiting oncoretroviral-mediated gene therapy to actively dividing target cells. In contrast, lentiviral vectors can transduce both dividing and nondividing cells. Lentiviral vectors have been derived from either human or primate lentiviruses, with the human immunodeficiency virus (HIV) as prototype, or from nonprimate lentiviruses, such as the equine infectious anemia virus (EIAV). The ability to pseudotype oncoretroviral and lentiviral vectors with the vesicular stomatitis virus G glycoprotein (VSV-G) allowed for the production of high-titer vectors (10 9-10 transducing units/ml). These high-titer vector preparations were shown to effectively cure genetic diseases in experimental animal models and constitute an essential step toward direct in vivo gene therapy applications. This chapter focuses on different methods that permit large-scale production of high-titer VSV-G pseudotyped oncoretroviral and primate or nonprimate lentiviral vectors and highlights their importance for achieving therapeutic effects in preclinical animal models.",
author = "Thierry VandenDriessche and Luigi Naldini and Desire Collen and Chuah, {Marinee K L}",
year = "2002",
doi = "10.1016/S0076-6879(02)46078-8",
language = "English",
volume = "346",
pages = "573--589",
journal = "ImmunoMethods",
issn = "1046-2023",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Oncoretroviral and lentiviral vector-mediated gene therapy

AU - VandenDriessche, Thierry

AU - Naldini, Luigi

AU - Collen, Desire

AU - Chuah, Marinee K L

PY - 2002

Y1 - 2002

N2 - Oncoretroviral vectors and lentiviral vectors offer the potential for long-term gene expression by virtue of their stable chromosomal integration and lack of viral gene expression. Consequently, their integration allows passage of the transgene to all progeny cells, which makes them particularly suitable for stem cell transduction. However, a disadvantage of oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV) is that cell division is required for transduction and integration, thereby limiting oncoretroviral-mediated gene therapy to actively dividing target cells. In contrast, lentiviral vectors can transduce both dividing and nondividing cells. Lentiviral vectors have been derived from either human or primate lentiviruses, with the human immunodeficiency virus (HIV) as prototype, or from nonprimate lentiviruses, such as the equine infectious anemia virus (EIAV). The ability to pseudotype oncoretroviral and lentiviral vectors with the vesicular stomatitis virus G glycoprotein (VSV-G) allowed for the production of high-titer vectors (10 9-10 transducing units/ml). These high-titer vector preparations were shown to effectively cure genetic diseases in experimental animal models and constitute an essential step toward direct in vivo gene therapy applications. This chapter focuses on different methods that permit large-scale production of high-titer VSV-G pseudotyped oncoretroviral and primate or nonprimate lentiviral vectors and highlights their importance for achieving therapeutic effects in preclinical animal models.

AB - Oncoretroviral vectors and lentiviral vectors offer the potential for long-term gene expression by virtue of their stable chromosomal integration and lack of viral gene expression. Consequently, their integration allows passage of the transgene to all progeny cells, which makes them particularly suitable for stem cell transduction. However, a disadvantage of oncoretroviral vectors based on Moloney murine leukemia virus (MoMLV) is that cell division is required for transduction and integration, thereby limiting oncoretroviral-mediated gene therapy to actively dividing target cells. In contrast, lentiviral vectors can transduce both dividing and nondividing cells. Lentiviral vectors have been derived from either human or primate lentiviruses, with the human immunodeficiency virus (HIV) as prototype, or from nonprimate lentiviruses, such as the equine infectious anemia virus (EIAV). The ability to pseudotype oncoretroviral and lentiviral vectors with the vesicular stomatitis virus G glycoprotein (VSV-G) allowed for the production of high-titer vectors (10 9-10 transducing units/ml). These high-titer vector preparations were shown to effectively cure genetic diseases in experimental animal models and constitute an essential step toward direct in vivo gene therapy applications. This chapter focuses on different methods that permit large-scale production of high-titer VSV-G pseudotyped oncoretroviral and primate or nonprimate lentiviral vectors and highlights their importance for achieving therapeutic effects in preclinical animal models.

UR - http://www.scopus.com/inward/record.url?scp=0036371516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036371516&partnerID=8YFLogxK

U2 - 10.1016/S0076-6879(02)46078-8

DO - 10.1016/S0076-6879(02)46078-8

M3 - Article

C2 - 11883092

AN - SCOPUS:0036371516

VL - 346

SP - 573

EP - 589

JO - ImmunoMethods

JF - ImmunoMethods

SN - 1046-2023

M1 - 33

ER -